Related Experiment Videos
Biological response modifiers
1Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy.
Abstract:
Biological response modifiers (BRMs) of current clinical interest may be divided into two categories: immunomodulating agents and colony stimulating factors (CSFs). The first are employed to potentiate the host defences towards the tumor but results have proved disappointing in non-small cell lung cancer (NSCLC). With regard to the second, the real dose increment which may be ascribed to CSFs is not sufficient to overcome chemoresistance of NSCLCs. CSFs can, however, reduce the hematologic toxicity of chemotherapy, which represents the most significant result.
Insights
Biological response modifiers (BRMs) show limited efficacy in non-small cell lung cancer (NSCLC) treatment. Colony stimulating factors (CSFs) primarily help reduce chemotherapy
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Biological response modifiers (BRMs) are investigated for cancer treatment.
- BRMs include immunomodulating agents and colony stimulating factors (CSFs).
- Their efficacy in non-small cell lung cancer (NSCLC) is under scrutiny.
Purpose of the Study:
- To evaluate the effectiveness of BRMs, specifically immunomodulating agents and CSFs, in treating NSCLC.
- To assess the potential of CSFs in overcoming chemotherapy resistance in NSCLC.
- To determine the clinical benefits of CSFs in managing chemotherapy-related toxicity.
Main Methods:
- Review of current clinical data on BRMs in NSCLC.
- Analysis of immunomodulating agents' impact on host defenses against NSCLC.
- Evaluation of CSFs' role in dose escalation and toxicity management for NSCLC chemotherapy.
Main Results:
- Immunomodulating agents have shown disappointing results in NSCLC.
- CSFs do not provide sufficient dose escalation to overcome NSCLC chemoresistance.
- CSFs significantly reduce the hematologic toxicity associated with chemotherapy for NSCLC.
Conclusions:
- BRMs, particularly immunomodulating agents, have limited direct therapeutic benefit in NSCLC.
- CSFs offer a valuable supportive role in NSCLC treatment by mitigating chemotherapy's side effects.
- The primary clinical utility of CSFs in NSCLC lies in managing treatment-induced hematologic toxicity.